

EXHIBIT LIST

The Sarcoma Foundation and The Alliance Against Alveolar Soft Part Sarcoma Citizen Petition

Exhibit

- A** National Cancer Institute, U.S. National Institutes of Health, Dictionary of Cancer Terms, “sarcoma”
- B** National Cancer Institute, A Snapshot of Sarcoma (September 2006)
- C** Portera, C.A., *et al.*, Alveolar Soft Part Sarcoma – Clinical Course and Patterns of Metastases in 70 Patients Treated at a Single Institution, *Am. Cancer Society* 2001; 91(3):585-591
- D** Kayton, M.L., *et al.*, Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults, *J. Ped. Surgery*, 2006; 41: 187-193
- E** Raretumours.org, Rare Tumors List
- F** Commission Regulation 507/2006, 2006 O.J. (L 92/6)
- G** EMEA Human Medicines – EMEA Pre-Submission Guidance, Questions & Answers, 44. Could my application qualify for a conditional marketing authorization?
- H** Commission Regulation 726/2004, art. 14(8), 2004 O.J. (L 136/1)
- I** Council Directive 2001/83/EC, as amended, art. 22, 2001 O.J. (L 311/67)
- J** Directive 2003/63/EC, Annex I, Part II, § 6, 2003 O.J. (L 159/46)
- K** EMEA, Committee for Medicinal Products for Human Use, Guideline on Procedures for the Granting of a Marketing Authorisation Under Exceptional Circumstances, Pursuant to Article 14(8) of Regulation (EC) No. 726/2004 (December 15, 2005)
- L** EMEA Human Medicines – EMEA Pre-Submission Guidance, Questions & Answers, 32. Marketing authorization under exceptional circumstances